Emergency Contraception at BMI 38: Does Levonorgestrel Still Work as Well
A time-sensitive contraceptive failure meets a genuinely contested efficacy question — whether levonorgestrel still works as well at her weight, and what to actually tell her about it in the next few hours.
Tanya B., a 33-year-old woman, works as a warehouse operations supervisor and called the clinic this morning after a condom failure last night, roughly fourteen hours ago, asking specifically about the "morning-after pill" she's used before without complication. She has no known contraindications to any of the emergency contraception options, isn't currently on a hormonal method, and has a same-day opening but a genuinely tight window before her shift starts this afternoon.
Her BMI, at 38, sits inside a range where levonorgestrel's efficacy is genuinely, not just theoretically, disputed. Several pharmacokinetic and outcome studies have found reduced levonorgestrel efficacy at higher weight and BMI thresholds, more pronounced than the signal for ulipristal acetate, though neither the FDA label nor WHO or ACOG guidance has changed to formally restrict levonorgestrel by weight — the position from every major body has instead been that access shouldn't be denied on the basis of an unsettled efficacy question, particularly given levonorgestrel's over-the-counter availability and speed. A copper IUD, placed within the same window, remains the single most effective emergency contraceptive option available and its effectiveness is essentially unaffected by weight — but it requires a procedure and an appointment slot, not a prescription she can fill on the way to work. That tradeoff is sharper for Tanya specifically than the guidance suggests in the abstract: ulipristal requires a prescription she does not yet have in hand, and if the tight window before her shift starts is the constraint that actually decides this, the theoretically stronger option may not be the practically available one in the next few hours — a nearby pharmacy would need to actually stock ulipristal and fill it before she clocks in, which is not guaranteed the way a levonorgestrel purchase off the shelf is. This is also the second time in three years she has needed emergency contraception, both times after condom failures rather than a missed dose of an ongoing method — a pattern worth naming to her directly once today's immediate question is settled, since it argues for a longer-term method more than either single visit does on its own, and a conversation better held once she isn't also watching the clock before her shift.
Same-day call, tight window before her shift
Nothing about her weight should keep levonorgestrel off the table. The label carries no weight-based restriction, and WHO and ACOG have both been explicit that access shouldn't be denied on the strength of a still-developing efficacy signal — especially for a drug she can get over the counter in the next hour rather than wait on an appointment for.
If the efficacy data were settled and dramatic rather than contested, I'd weigh this differently — this is specifically about not letting an unsettled signal become a practical barrier.
I'm not arguing for denying her access — I'm arguing she deserves to hear the actual efficacy picture, not have it smoothed into "take whichever one you can get." Several pharmacokinetic and outcome studies have found levonorgestrel's efficacy declining at BMI thresholds like hers, more than the signal for ulipristal, and a copper IUD's effectiveness is essentially unaffected by weight and is the single most effective EC option at any BMI. If a same-day IUD slot exists, that's worth naming as the option with the least uncertainty, not just one alternative among several.
I'd agree access shouldn't be denied — my point is that "not denying access" and "not mentioning a real efficacy difference" aren't the same thing, and she can't weigh what she isn't told.
Given her actual timeline, the practical question is what's reachable in the next few hours, not just what's theoretically best. If the same-day IUD slot genuinely fits before her shift, that's the option with both the highest overall effectiveness and the least weight-related uncertainty. If it doesn't fit her schedule, ulipristal acetate retains efficacy at a higher BMI threshold than levonorgestrel in the same pharmacokinetic literature and doesn't require a procedure — the better oral option specifically, not levonorgestrel by default just because it's more familiar to her.
Agreed: Tanya was told the actual efficacy picture directly, including the contested weight-related signal for levonorgestrel, and the same-day IUD slot was confirmed to fit before her shift. She chose the IUD once she heard it carried both the highest effectiveness and the least uncertainty, with ulipristal named clearly as what she'd have been offered instead had the appointment not fit her timeline. All three positions converged on the same practical path once access, evidence, and logistics were treated as three separate questions rather than folded into one.